Provided by Tiger Trade Technology Pte. Ltd.

Elicio Therapeutics

1.77
-0.2200-11.06%
Post-market: 1.800.0291+1.64%19:49 EDT
Volume:629.87K
Turnover:1.15M
Market Cap:46.52M
PE:-0.81
High:1.90
Open:1.90
Low:1.71
Close:1.99
52wk High:16.00
52wk Low:1.71
Shares:26.28M
Float Shares:19.19M
Volume Ratio:1.61
T/O Rate:3.28%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1721
EPS(LYR):-2.5842
ROE:-774.56%
ROA:-77.88%
PB:5.86
PE(LYR):-0.68

Loading ...

Elicio Therapeutics announces pricing of $15M registered direct offering

TIPRANKS
·
Jul 02

Elicio Therapeutics Prices $15 Million Direct Offering

MT Newswires Live
·
Jul 02

Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering

THOMSON REUTERS
·
Jul 02

Elicio Therapeutics Added to Russell 2000® and Russell 3000® Indexes

GlobeNewswire
·
Jun 29

Elicio Therapeutics Posts Amplify-7p Presentation on Eli-002 7P in Metastatic Mkras Pancreatic Cancer

Reuters
·
Jun 25

Analysts Conflicted on These Healthcare Names: Phathom Pharmaceuticals (PHAT) and Elicio Therapeutics (ELTX)

TIPRANKS
·
Jun 25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Damora Therapeutics (DMRA), Summit Therapeutics (SMMT) and Elicio Therapeutics (ELTX)

TIPRANKS
·
Jun 22

Elicio Therapeutics Coverage Assumed by Ladenburg Thalmann at Buy

Dow Jones
·
Jun 19

Elicio Therapeutics assumed with a Buy at Ladenburg

TIPRANKS
·
Jun 18

Top Premarket Decliners

MT Newswires Live
·
Jun 18

Elicio Reports Complete Responses in 3 Pancreatic Cancer Patients After ELI-002 7P, Nivolumab Treatment

MT Newswires Live
·
Jun 17

Elicio Therapeutics reports complete responses in pancreatic cancer trial

TIPRANKS
·
Jun 17

Elicio Therapeutics plans Phase 1 trial of ELI-002 7P plus anti-PD-1, chemo in metastatic mKRAS pancreatic cancer

Reuters
·
Jun 17

Elicio Therapeutics - Complete Responses Observed in Mss/Mmr-P Patients With Historically Checkpoint Inhibitor Response

THOMSON REUTERS
·
Jun 17

Elicio Therapeutics - Reports 100% Confirmed Complete Responses in Three Patients After Eli-2 7P and Nivolumab

THOMSON REUTERS
·
Jun 17

Elicio Therapeutics - Two Patients Maintain Complete Responses for at Least Eight Months, One Over 13 Months

THOMSON REUTERS
·
Jun 17

Elicio Therapeutics - Plans to Initiate Phase 1 Study in Metastatic Pancreatic Ductal Adenocarcinoma

THOMSON REUTERS
·
Jun 17

Elicio Therapeutics Reports Multiple Complete Responses After Eli-002 7P Treatment and Subsequent Therapy With Checkpoint Inhibition in Metastatic Mkras Pancreatic Cancer

THOMSON REUTERS
·
Jun 17

SueWallSt opens probe into Elicio Therapeutics officers, directors after 72.53% stock plunge

Reuters
·
Jun 17

Elicio Therapeutics Cut to Hold From Buy by Jones Trading

Dow Jones
·
Jun 17